Want to see HK:0474 full AI Analyst Report?
Top Page
Aceso Life Science Group Limited
(0474)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$0.16
▲(30.00% Upside)
Action:Reiterated
Date:08/29/26
The score is primarily held back by weak and volatile financial performance, including heavy leverage and inconsistent operating results despite a recent rebound. Technicals are supportive given the uptrend and positive MACD, but overbought readings add near-term risk. Valuation helps with a low P/E, though the lack of dividend data limits additional support.
Positive Factors
Profitability rebound
The return to reported profitability improves near-term financial resilience and may support reinvestment or debt servicing. However, the rebound should be monitored because weak operating margins indicate that its durability is not yet established.
Negative Factors
Sharp revenue contraction
A steep decline in revenue highlights an unstable top-line trajectory and makes fixed-cost absorption more difficult. Unless demand and business activity recover, the contraction can constrain operating leverage and undermine the recent earnings rebound.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability rebound
The return to reported profitability improves near-term financial resilience and may support reinvestment or debt servicing. However, the rebound should be monitored because weak operating margins indicate that its durability is not yet established.
Read all positive factors
Aceso Life Science Group Limited (0474) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.34B
Dividend Yield1.2%
Average Volume (3M)4.59M
Price to Earnings (P/E)3.2
Beta (1Y)0.17
Revenue Growth-68.22%
EPS GrowthN/A
CountryHK
Employees28
SectorIndustrials
Sector Strength72
IndustryRental & Leasing Services
Share Statistics
EPS (TTM)0.05
Shares Outstanding8,858,127,000
10 Day Avg. Volume2,017,690
30 Day Avg. Volume4,591,705
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.53
Price to Sales (P/S)10.91
P/FCF Ratio34.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aceso Life Science Group Limited Business Overview & Revenue Model
Company Description
Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom. It operates through rental and sale of...
Aceso Life Science Group Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
41
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 64.00M | 195.00M | 11.00M | 312.00M | 315.00M |
| Gross Profit | 54.00M | 90.00M | -100.00M | 141.00M | 162.00M |
| EBITDA | -297.00M | -860.00M | -220.00M | -21.00M | -359.00M |
| Net Income | 338.00M | -895.00M | -462.00M | -264.00M | -370.00M |
Balance Sheet | |||||
| Total Assets | 1.79B | 3.24B | 4.79B | 6.30B | 6.26B |
| Cash, Cash Equivalents and Short-Term Investments | 345.00M | 207.00M | 466.00M | 602.00M | 717.00M |
| Total Debt | 1.19B | 2.30B | 2.74B | 2.34B | 3.01B |
| Total Liabilities | 1.33B | 2.50B | 2.97B | 3.73B | 3.44B |
| Stockholders Equity | 457.00M | 12.00M | 921.00M | 1.55B | 2.00B |
Cash Flow | |||||
| Free Cash Flow | 20.00M | 15.00M | -48.00M | 175.00M | 259.00M |
| Operating Cash Flow | 20.00M | 17.00M | -37.00M | 222.00M | 316.00M |
| Investing Cash Flow | 674.00M | 337.00M | 472.00M | -120.00M | -441.00M |
| Financing Cash Flow | -681.00M | -587.00M | 117.00M | -98.00M | 126.00M |
Aceso Life Science Group Limited Technical Analysis
Positive
0.12
Price Trends
0.12
Positive
0.12
Positive
0.12
Positive
Market Momentum
<0.01
Positive
63.86
Neutral
65.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0474, the sentiment is Positive. The current price of 0.12 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.12, and above the 200-day MA of 0.12, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 63.86 is Neutral, neither overbought nor oversold. The STOCH value of 65.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0474.
Aceso Life Science Group Limited Peers Comparison
UnderperformOutperform
Sector (63)
HK:0474
Aceso Life Science Group Limited
0.15
0.13
655.00%
HK:2327
Meilleure Health International Industry Group Limited
0.24
-0.03
-10.82%
Aceso Life Science Group Limited Corporate Events
Aceso Life Science Sets 2026 AGM to Renew Mandates and Expand Share Issuance Authority
Aug 20, 2026
Aceso Life Science Group Limited, a Cayman-incorporated company listed in Hong Kong under stock code 00474, operates in the life sciences sector with a focus on health-related businesses and investment in healthcare markets. Its governance framewo...
Aceso Life Science to Resume Trading in Hong Kong After Publishing Delayed 2026 Results
Aug 13, 2026
Aceso Life Science Group Limited, a Cayman Islands-incorporated life sciences company listed in Hong Kong, operates under the oversight of a mixed board of executive, non-executive and independent non-executive directors. Its shares are traded on ...
Aceso Life Science Swings to Annual Profit on Discontinued Operations Gain
Aug 13, 2026
Aceso Life Science Group Limited, a Hong Kong-listed life sciences-focused investment and operating group, derives its results from a combination of core operations and valuation changes in investment properties and financial assets. The company&#...
Aceso Life Science Delays Dispatch of Subscription Agreement Circular Again
Aug 5, 2026
Aceso Life Science Group Limited has announced a further delay in sending a shareholder circular related to a Subscription Agreement and the planned issuance of consideration shares under a specific mandate. The circular, which will include detail...
Aceso Life Science Sets Board Date as Share Trading Remains Suspended Pending Results
Aug 3, 2026
Aceso Life Science Group Limited has scheduled a board meeting for 13 August 2026 in Hong Kong to approve and publish its audited final results for the year ended 31 March 2026 and to consider whether to recommend a final dividend. The timing and ...
Aceso Life Science Signals Profit on Subsidiary Disposal as Trading Stays Suspended
Aug 3, 2026
Aceso Life Science Group Limited has issued a positive profit alert, indicating it expects to report a profit of about HK$336 million for the year ended 31 March 2026, compared with a loss of approximately HK$1,017 million a year earlier. The turn...
Aceso Life Science Delays Dispatch of Subscription Agreement Circular to Shareholders
Jul 2, 2026
Aceso Life Science Group Limited has announced a further delay in sending a shareholder circular related to a Subscription Agreement and the proposed issue of consideration shares under a specific mandate. The circular, which will include reports ...
Aceso Life Science Delays 2026 Results, Faces Trading Suspension in Hong Kong
Jul 2, 2026
Aceso Life Science Group Limited has announced it will miss the 30 June 2026 deadline to publish its audited annual results for the year ended 31 March 2026, citing the need for additional time to collect valuation data for certain financial asset...
Aceso Life Science Delays Board Meeting to Finalise 2026 Annual Results
Jun 24, 2026
Aceso Life Science Group Limited has postponed its planned board meeting, originally scheduled for 26 June 2026, to 30 June 2026 to allow more time for management to finalise its audited financial results for the year ended 31 March 2026. The meet...
Aceso Life Science Sets June Board Meeting to Approve 2026 Final Results
Jun 11, 2026
Aceso Life Science Group Limited has scheduled a board meeting in Hong Kong on 26 June 2026 to approve the audited final results for the financial year ended 31 March 2026 and to authorise their publication. The board will also consider whether to...
Aceso Life Science Trims Future Data Stake in HK$8.78 Million Share Disposal
Jun 8, 2026
Aceso Life Science Group Limited has disposed of 18.3 million shares in Future Data on the open market between 4 June and 8 June 2026, raising approximately HK$8.78 million at an average price of HK$0.48 per share. The sale, executed via the Hong ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.